JP2014524445A5 - - Google Patents

Download PDF

Info

Publication number
JP2014524445A5
JP2014524445A5 JP2014526241A JP2014526241A JP2014524445A5 JP 2014524445 A5 JP2014524445 A5 JP 2014524445A5 JP 2014526241 A JP2014526241 A JP 2014526241A JP 2014526241 A JP2014526241 A JP 2014526241A JP 2014524445 A5 JP2014524445 A5 JP 2014524445A5
Authority
JP
Japan
Prior art keywords
muc1
yeast
composition
immunotherapy
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014526241A
Other languages
English (en)
Japanese (ja)
Other versions
JP6122007B2 (ja
JP2014524445A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/051299 external-priority patent/WO2013025972A1/en
Publication of JP2014524445A publication Critical patent/JP2014524445A/ja
Publication of JP2014524445A5 publication Critical patent/JP2014524445A5/ja
Application granted granted Critical
Publication of JP6122007B2 publication Critical patent/JP6122007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014526241A 2011-08-17 2012-08-17 酵母−muc1免疫療法用組成物およびその使用 Active JP6122007B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524407P 2011-08-17 2011-08-17
US61/524,407 2011-08-17
PCT/US2012/051299 WO2013025972A1 (en) 2011-08-17 2012-08-17 Yeast-muc1 immunotherapeutic compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017067243A Division JP6306238B2 (ja) 2011-08-17 2017-03-30 酵母−muc1免疫療法用組成物およびその使用

Publications (3)

Publication Number Publication Date
JP2014524445A JP2014524445A (ja) 2014-09-22
JP2014524445A5 true JP2014524445A5 (OSRAM) 2015-10-01
JP6122007B2 JP6122007B2 (ja) 2017-04-26

Family

ID=47715495

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014526241A Active JP6122007B2 (ja) 2011-08-17 2012-08-17 酵母−muc1免疫療法用組成物およびその使用
JP2017067243A Active JP6306238B2 (ja) 2011-08-17 2017-03-30 酵母−muc1免疫療法用組成物およびその使用
JP2018040308A Active JP6571822B2 (ja) 2011-08-17 2018-03-07 酵母−muc1免疫療法用組成物およびその使用
JP2019145946A Pending JP2019194261A (ja) 2011-08-17 2019-08-08 酵母−muc1免疫療法用組成物およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017067243A Active JP6306238B2 (ja) 2011-08-17 2017-03-30 酵母−muc1免疫療法用組成物およびその使用
JP2018040308A Active JP6571822B2 (ja) 2011-08-17 2018-03-07 酵母−muc1免疫療法用組成物およびその使用
JP2019145946A Pending JP2019194261A (ja) 2011-08-17 2019-08-08 酵母−muc1免疫療法用組成物およびその使用

Country Status (13)

Country Link
US (3) US9533031B2 (OSRAM)
EP (1) EP2744918A4 (OSRAM)
JP (4) JP6122007B2 (OSRAM)
KR (1) KR102049928B1 (OSRAM)
CN (3) CN104024429B (OSRAM)
AU (3) AU2012296425B2 (OSRAM)
BR (1) BR112014003477B1 (OSRAM)
CA (1) CA2844500C (OSRAM)
IL (2) IL230863B (OSRAM)
MX (1) MX352892B (OSRAM)
RU (2) RU2017143985A (OSRAM)
SG (1) SG10201607663YA (OSRAM)
WO (1) WO2013025972A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
WO2012083302A2 (en) 2010-12-17 2012-06-21 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
CN103476426B (zh) 2011-02-12 2021-08-10 全球免疫股份有限公司 用于慢性乙型肝炎病毒感染的基于酵母的治疗剂
HUE033491T2 (en) 2011-03-17 2017-12-28 Globeimmune Inc Yeast-brachyury immunotherapeutic compositions
US9579377B2 (en) 2011-06-14 2017-02-28 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
KR102049928B1 (ko) 2011-08-17 2019-11-28 글로브이뮨 효모-muc1 면역요법 조성물 및 그 용도
JP6523685B2 (ja) * 2012-01-03 2019-06-05 アメリカ合衆国 Muc1腫瘍抗原のネイティブ及びアゴニストctlエピトープ
US9653272B2 (en) 2012-06-26 2017-05-16 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
US10507235B2 (en) 2013-03-19 2019-12-17 Globeimmune, Inc. Yeast-based immunotherapy for Chordoma
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
JP6788500B2 (ja) * 2013-10-23 2020-11-25 アメリカ合衆国 Muc1−c癌タンパク質のhla−a24アゴニストエピトープ及び組成物及び使用方法
CN106456677B (zh) 2014-04-11 2025-06-03 全球免疫股份有限公司 基于酵母的免疫疗法和i型干扰素敏感性
WO2016105536A2 (en) * 2014-12-23 2016-06-30 University Of Maryland, Baltimore Muc1 decoy peptides for treatment and prevention of bacterial infections
JP6647315B2 (ja) * 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
KR20170102002A (ko) 2015-01-09 2017-09-06 이투빅스 코포레이션 에볼라 바이러스 백신접종을 위한 방법 및 조성물
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
AU2016303525B2 (en) 2015-08-03 2021-01-21 Globeimmune, Inc. Modified yeast-Brachyury immunotherapeutic compositions
EP3383427A4 (en) * 2015-12-04 2019-11-27 Mayo Foundation for Medical Education and Research METHOD AND VACCINES FOR INDUCTION OF IMMUNE REACTIONS TO SEVERAL DIFFERENT MHC MOLECULES
US20190183870A1 (en) 2016-01-05 2019-06-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
TWI654302B (zh) 2016-01-19 2019-03-21 輝瑞股份有限公司 癌症疫苗
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
SG11201807770RA (en) 2016-03-24 2018-10-30 Nantcell Inc Sequence arrangements and sequences for neoepitope presentation
AU2018258119B2 (en) 2017-04-24 2021-04-01 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
CN112543640B (zh) 2018-05-15 2025-02-14 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
JP2023522015A (ja) * 2020-04-17 2023-05-26 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク サルコペニアを逆行させる方法、組成物及びその使用
CN113214210B (zh) 2021-05-10 2022-03-04 合肥立方制药股份有限公司 一种二氢槲皮素的制备方法
CN113185485B (zh) 2021-05-10 2022-03-04 合肥立方制药股份有限公司 一种二氢槲皮素的半合成方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
AU727308B2 (en) 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen
DE19758400A1 (de) 1997-12-30 1999-07-01 Max Delbrueck Centrum Tumorvakzine für MUC1-positive Karzinome
JP4409097B2 (ja) 1998-12-09 2010-02-03 アメリカ合衆国 複数の共刺激分子を発現する組換えベクターおよびその利用
DE19906615A1 (de) * 1999-02-17 2000-09-28 Hanisch Franz Georg Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung
DE60030450T2 (de) * 1999-09-08 2007-08-30 Transgene S.A. Von MUC-1 abgeleitete Peptide
DE10006753A1 (de) 2000-02-15 2001-08-16 Zeiss Carl Dreh-Schwenkeinrichtung für den Tastkopf eines Koordinatenmeßgerätes
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
ATE359295T1 (de) * 2002-06-11 2007-05-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzungen
US20060051759A1 (en) * 2002-06-14 2006-03-09 Susana Salceda Compositions and methods relating to breast specific genes and proteins
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN104147597A (zh) * 2002-12-16 2014-11-19 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
JP5285855B2 (ja) * 2003-11-12 2013-09-11 アメリカ合衆国 膵癌を処置および予防するためのカスタムベクター
EP1687334B1 (en) * 2003-11-24 2014-01-08 MicroVAX, LLC Mucin antigen vaccine
JP2008504219A (ja) * 2003-12-11 2008-02-14 シドニー キンメル キャンサー センター 抗原に対する免疫を生じさせる方法
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
CA2547635C (en) 2003-12-12 2016-02-09 Jeffrey Schlom A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
BRPI0613025A2 (pt) * 2005-07-11 2010-12-14 Globeimmune Inc composiÇço para reduzir a resistÊncia a um agente, mÉtodo para a preparaÇço de um veÍculo de levedura e uso da composiÇço
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
EP2021366A2 (en) * 2006-01-23 2009-02-11 Recopharma AB Production of proteins carrying oligomannose or human-like glycans in yeast and methods use thereof
JP5198290B2 (ja) 2006-02-02 2013-05-15 グローブイミューン,インコーポレイテッド 免疫反応を誘発する酵母ベースワクチン
KR20090008290A (ko) 2006-03-27 2009-01-21 글로브이뮨 Ras 돌연변이와 그에 관련된 조성물 및 방법
KR20150006022A (ko) 2007-02-02 2015-01-15 글로브이뮨 효모계 백신의 제조방법
JP5579451B2 (ja) 2007-03-19 2014-08-27 グローブイミューン,インコーポレイテッド ガンのための標的化治療の変異性回避の標的化アブレーションのための組成物
US20100278873A1 (en) 2007-11-08 2010-11-04 David Avigan Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
JP5657549B2 (ja) * 2008-10-17 2015-01-21 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 癌の阻害剤としてのmuc−1細胞質ドメインペプチド
WO2010065626A1 (en) * 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
KR101781966B1 (ko) * 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
WO2011115914A1 (en) 2010-03-14 2011-09-22 Globeimmune, Inc. Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
WO2012083302A2 (en) 2010-12-17 2012-06-21 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
CN103476426B (zh) 2011-02-12 2021-08-10 全球免疫股份有限公司 用于慢性乙型肝炎病毒感染的基于酵母的治疗剂
HUE033491T2 (en) 2011-03-17 2017-12-28 Globeimmune Inc Yeast-brachyury immunotherapeutic compositions
US9579377B2 (en) 2011-06-14 2017-02-28 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
KR102049928B1 (ko) 2011-08-17 2019-11-28 글로브이뮨 효모-muc1 면역요법 조성물 및 그 용도

Similar Documents

Publication Publication Date Title
JP2014524445A5 (OSRAM)
ZA202308845B (en) Cx3cr1-binding polypeptides
JP2011155981A5 (OSRAM)
HK1216894A1 (zh) 多價結合蛋白組合物
MX351502B (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
CL2012002095A1 (es) Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa
NZ616761A (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
WO2015051199A3 (en) Modified pseudomonas exotoxin a
NZ761188A (en) Antibody molecules to tim-3 and uses thereof
JP2016185981A5 (OSRAM)
MY176331A (en) Carbohydrate degrading polypeptide and uses thereof
MX380772B (es) 3-epimerasa.
IN2014DN00202A (OSRAM)
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
JP2014525439A5 (OSRAM)
WO2015160928A3 (en) Isolated t cell receptors and methods of use therefor
PH12015500771A1 (en) Novel fc gamma receptor iib variants
MX374403B (es) Secuencia de endolisina kz144 modificada.
HK1201850A1 (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
WO2015002631A3 (en) Asymmetrical multilateral decision support system
WO2014202208A8 (fr) Polypeptide ayant la capacite de former des branchements d'unites glucosyle en alpha-1,3 sur un accepteur
NZ702285A (en) Staphylococcal coagulase antigens and methods of their use
WO2014152247A8 (en) Improved tnf binding proteins
WO2014078213A3 (en) Modified apol1 polypeptides
EP4461371A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers